Flegnil Syrup

Introduction

Flegnil Syrup 125 mg/5 ml is a mucolytic agent used to treat conditions associated with excessive mucus production, such as chronic obstructive pulmonary disease (COPD) and chronic bronchitis. It helps to reduce the viscosity of mucus, making it easier to clear from the airways.

Uses

Flegnil Syrup 125 mg/5 ml is used for:

Managing chronic respiratory conditions characterized by thick, sticky mucus, such as COPD and chronic bronchitis.
Reducing mucus viscosity in conditions like asthma with excessive mucus production.

It helps improve respiratory function and ease symptoms related to mucus accumulation.

Brand Name	Flegnil
Type	Syrup
Weight	125 mg/5 ml
Generic	Carbocisteine
Manufacturer	Orion Pharma Ltd.
Available in	English বাংলা

Mechanism of Action

Flegnil Syrup 125 mg/5 ml works by breaking down the disulfide bonds in mucus, thereby reducing its viscosity and elasticity. This action makes the mucus less thick and sticky, facilitating its removal from the respiratory tract through coughing or expectoration.

How Long Does It Take to Work?

Flegnil Syrup 125 mg/5 ml typically starts to show effects within a few days of starting treatment. Maximum benefit may be observed within 1-2 weeks of consistent use, depending on the severity of the condition and individual response.

Absorption

Flegnil Syrup 125 mg/5 ml is well absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations are usually reached within 1-2 hours after ingestion.

Route of Elimination

Flegnil Syrup 125 mg/5 ml is primarily eliminated through the urine. It is metabolized in the liver before being excreted as metabolites. The drug’s half-life influences the duration of its action and effectiveness.

Dosage

Adults (including elderly): Dosage is based upon an initial dosage of 2250 mg daily in divided doses (750 mg 3 times daily), reduced to 1500 mg daily in divided doses (375 mg 4 times daily), when a satisfactory response has been obtained.

Children: Normal daily dose is 20 mg/kg body weight in divided doses.
2-5 years: 62.5-125 mg 4 times daily.
6-12 years: 250 mg 3 times daily.
Infants: Dosage in infants has not been established.

The dosage of carbocisteine can vary based on the condition being treated and patient characteristics. Typical dosages are:

For adults: 750 mg to 1,500 mg per day, divided into 2-3 doses.
For children: Dosage is adjusted based on weight and age, usually 20 mg/kg/day divided into 2-3 doses.

Dosage should be tailored to individual needs and clinical response, with adjustments as necessary based on tolerability and effectiveness.

Administration

Flegnil Syrup 125 mg/5 ml is administered orally in the form of tablets, capsules, or syrup. It should be taken with or without food as directed by a healthcare provider. Consistent dosing at the same times each day helps maintain effective drug levels.

Side Effects

Common side effects of carbocisteine include:

Gastrointestinal symptoms such as nausea, vomiting, and diarrhea.
Stomach upset or abdominal pain.
Skin rash or itching.

Serious side effects are rare but may include:

Severe allergic reactions or anaphylaxis.
Severe gastrointestinal disturbances.

Contact a healthcare provider if serious side effects occur.

Toxicity

Toxicity from carbocisteine is uncommon but can occur, particularly with overdose. Symptoms of toxicity may include severe gastrointestinal symptoms and allergic reactions. Immediate medical attention is required in the event of overdose or severe reactions.

Precautions

Precautions for carbocisteine use include:

Use with caution in patients with a history of gastrointestinal disorders or ulcers.
Monitor for any signs of adverse reactions, especially gastrointestinal disturbances.
Consult with a healthcare provider before using in combination with other medications or if you have underlying health conditions.

Interaction

Flegnil Syrup 125 mg/5 ml may interact with:

Other medications affecting the gastrointestinal tract, such as antacids or other mucolytics.
Medications that influence liver metabolism.

Inform your healthcare provider of all medications and supplements you are taking to manage potential interactions.

Disease Interaction

Flegnil Syrup 125 mg/5 ml should be used with caution in:

Patients with a history of gastrointestinal diseases, such as ulcers or gastrointestinal bleeding.
Individuals with liver impairment, as it may affect drug metabolism and clearance.

Regular monitoring is recommended in these populations.

Drug Interaction

Drug interactions include:

Potential interactions with other drugs affecting mucus production or gastrointestinal motility.
Altered effects when used with drugs that impact liver function or enzyme systems.

Consult with your healthcare provider to avoid or manage interactions effectively.

Food Interactions

No significant food interactions are known with carbocisteine. It can be taken with or without food. Maintaining a balanced diet may help manage overall health and symptom control.

Pregnancy Use

Flegnil Syrup 125 mg/5 ml is classified as Category B for pregnancy, meaning there is no evidence of harm to the fetus in animal studies, but there are limited human studies. It should be used during pregnancy only if clearly needed and prescribed by a healthcare provider.

Lactation Use

Flegnil Syrup 125 mg/5 ml is excreted in breast milk in small amounts. Use during lactation should be evaluated by a healthcare provider, considering the potential benefits and risks to the infant. Alternatives or adjustments may be recommended based on individual circumstances.

Acute Overdose

In the event of an acute overdose, symptoms may include severe gastrointestinal distress and potential allergic reactions. Immediate medical attention is necessary, and treatment will involve supportive care and symptomatic management.

Contraindication

Flegnil Syrup 125 mg/5 ml is contraindicated in:

Patients with hypersensitivity to carbocisteine or any of its components.
Individuals with severe gastrointestinal disorders or active peptic ulcers.

Ensure a thorough review of patient history before initiating therapy.

Use Direction

Follow the prescribed dosage and administration directions carefully. Do not adjust the dose or frequency without consulting a healthcare provider. Regular follow-up and monitoring are important to assess efficacy and manage any potential side effects.

Storage Conditions

Store carbocisteine tablets or syrup at room temperature, away from moisture and direct light. Keep out of reach of children and do not use after the expiration date. Dispose of unused medication properly.

Volume of Distribution

The volume of distribution of carbocisteine is not well-defined but it is distributed throughout the body after absorption. The drug acts locally in the respiratory tract, where it helps in reducing mucus viscosity.

Half Life

The half-life of carbocisteine is approximately 1-2 hours. This relatively short half-life necessitates multiple doses throughout the day to maintain effective drug levels.

Clearance

Flegnil Syrup 125 mg/5 ml is primarily cleared by the kidneys. It is important to monitor renal function in patients with impaired kidney function to avoid accumulation and potential adverse effects.

See in details version Flegnil Syrup 125 mg/5 ml also Flegnil Syrup 125 mg/5 ml in bangla